Jeffrey D. Dunn, PharmD, MBA, leads a panel discussion on disease and treatment landscapes for COPD. Jeffrey D. Dunn, PharmD, MBA: Hello, and welcome to this AJMC® program titled “Medication ...

Patients with COPD and heart failure treated with SGLT-2 inhibitors experienced higher rates of volume depletion and adverse renal events. Chronic obstructive pulmonary disease (COPD) reduces the ...

Chronic obstructive pulmonary disease (COPD) significantly heightens the risk of mortality and hospitalization in patients with heart failure with preserved ejection fraction (HFpEF). Despite this, ...

Cardiovascular diseases and diabetes are some of the most common coexisting conditions in COPD. Shared risk factors and overlapping physiological processes likely contribute to the high rate of ...

Prediction of immune-related adverse events in urological cancer during checkpoint inhibitor immunotherapy through immunohistochemical analysis of tumorous LCP1/ADPGK. This is an ASCO Meeting Abstract ...

Please provide your email address to receive an email when new articles are posted on . Health care resource utilization captured ED and hospital visits related to COPD. Among adults with COPD, GERD ...

Please provide your email address to receive an email when new articles are posted on . Researchers found significantly reduced odds for hypertension and diabetes among those with bronchiectasis vs.

Patients with comorbid respiratory disease were significantly more likely to develop nontuberculosis mycobacterial pulmonary disease (NTM-PD), data from a systematic review of 99 studies indicate. NTM ...

Distinct COPD phenotypes show differences in severity and mortality, with worse outcomes linked to income, race, rural living, and smoking.